JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
Pre-market 08:05:04 am | |||
| 149.9 USD | +0.04% |
|
150.1 | +0.13% |
| 02:05pm | Johnson & Johnson to No Longer Own Kenvue Shares After Proposed Offering Closes | MT |
| 01:49pm | Johnson & Johnson to No Longer Own Kenvue Shares After Proposed Offering Closes | MT |
Presenter SpeechUnknown Attendee (Attendees)Welcome to the Johnson & Johnson 2018 Consumer and...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
149.9
USD
Average target price
173.3
USD
Spread / Average Target
+15.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.36% | 361B | |
| +30.38% | 684B | |
| +29.47% | 568B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +15.96% | 240B | |
| +9.34% | 208B | |
| -7.28% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Transcript : Johnson & Johnson - Analyst/Investor Day
